Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531817 | 0.88 | MAPT (0.54) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL4868930 | 0.86 | MAPT (0.49) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL21707873 | 0.84 | MAPT (0.47) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL19969998 | 0.84 | DRD2 (0.52) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL426519 | 0.83 | PARP10 (0.56) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL30564582 | 0.83 | PARP10 (0.56) | DRD2DRD4PARP10PARP11PARP1 | |
| Hydrochloric Acid SCHEMBL549603 | 0.81 | PARP10 (0.55) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL14619655 | 0.80 | DRD2 (0.47) | DRD2DRD4PARP10PARP11PARP1 | |
| SCHEMBL31504071 | 0.80 | PARP10 (0.64) | DRD2DRD4PARP10PARP11MAPT | |
| SCHEMBL31504072 | 0.79 | DRD2 (0.50) | DRD2DRD4PARP10PARP11PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 687 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229275-B | Novel 2-acetamido thiazole compound and preparation method and application thereof | 北京中医药大学 | 2024-06-18 | — | — | CN | claimed |
| WO-2024115863-A1 | FUEL COMPOSITION COMPRISING A RENEWABLE BASE AND A NITROGEN-CONTAINING HETEROCYCLIC AROMATIC COMPOUND | TOTALENERGIES ONETECH (FR) | 2024-06-06 | — | — | WO | claimed |
| CN-115353478-A | Preparation method of indole compound | 南京工业大学 | 2022-11-18 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | claimed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-0976731-B1 | PROCESS FOR PRODUCING 5-METHYLINDOLINES | IHARA CHEMICAL IND CO (JP) | 2002-09-25 | — | — | EP | claimed |
| US-6066744-A | Process for producing 5-methylindolines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-05-23 | — | — | US | claimed |
| EP-0976731-A1 | PROCESS FOR PRODUCING 5-METHYLINDOLINES | Ihara Chemical Industry Co., Ltd. (JP) | 2000-02-02 | — | — | EP | claimed |
| JP-10279557-A | — | — | None | — | — | JP | disclosed |
| CN-116145156-B | Indoline compound preparation method based on organic electronic synthesis | 六盘水师范学院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4692071-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-4723007-A | ANALGESICS, ANTIPSYCHOTIC AGENTS; INTERMEDIATES FOR PROCESSING | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-02-02 | — | — | US | disclosed |
| US-4663453-A | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-05-05 | — | — | US | disclosed |
| US-4617313-A | ANTIDEPRESSANTS | SYNTHELABO (FR) | 1986-10-14 | — | — | US | disclosed |
| EP-0129692-A2 | Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4159271-A | CYCLIZATION OF A 2-HALOGENOPHENETHYLAMINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | DRD2 4529/4885DRD4 4727/4885PARP10 705/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | DRD2 4401/4885DRD4 2097/4885PARP10 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.